Table 2.
Efficacy outcome by BPDAI and pruritus WI-NRS
| Patient No. | Response | WI-NRS (BL) | WI-NRS (day 1) | WI-NRS (day 3) | WI-NRS (day 14) | WI-NRS (month 1) | WI-NRS (month 2) | WI-NRS (last follow-up) | BPDAI (BL) | BPDAI (week 2) | BPDAI (month 1) | BPDAI (month 2) | BPDAI (last follow-up) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CR | 10 | NA | NA | 2 | 1 | 0 | 0 | 21 | 7 | 11 | 4 | 0 |
| 2 | CR | 10 | 2 | 1 | NA | 1 | 1 | 0 | 32 | 10 | 6 | 0 | 0 |
| 3 | CR | 10 | 4 | 1 | 1 | 1 | 1 | 0 | 39 | 12 | 1 | 1 | 0 |
| 4 | CR | 10 | 1 | 1 | 1 | 1 | 1 | 0 | 19 | NA | NA | NA | 0 |
| 5 | CR | 10 | 8 | 4 | 4 | 1 | 1 | 0 | 32 | 29 | 12 | 0 | 0 |
| 6 | CR | 10 | 7 | NA | 3 | 1 | 1 | 0 | 7 | NA | 0 | 0 | 0 |
| 7 | CR | 9 | 9 | 6 | 4 | 1 | 1 | 0 | 16 | 1 | 1 | 0 | 0 |
| 8 | PR | 10 | NA | NA | 6 | 4 | 1 | 1 | 22 | 20 | 7 | 8 | 8 |
| 9 | PR | 6 | 5 | 3 | 3 | 3 | 3 | 3 | 3 | 1 | NA | 0 | 0 |
| 10 | PR | 5 | 4 | 4 | 4 | NA | NA | NA | 26 | NA | ongoing | NA | NA |
| 11 | PR | 10 | 5 | 1 | 1 | 1 | NA | NA | 42 | 46 | 40 | switch | 21 |
| 12 | CR | 10 | 3 | 1 | 0 | 0 | 0 | 0 | 32 | 36 | 13 | 15 | 0 |
| MEAN | 10 | 5 | 1 | 3 | 1 | 1 | 0 | 24 | 12 | 7 | 0 | 0 | |
| SD | 1.7 | 2.6 | 1.9 | 1.8 | 1.1 | 0.8 | 1.0 | 12.0 | 15.9 | 12.3 | 5.2 | 6.5 |
BPDAI, bullous pemphigoid disease area index; BL, baseline; NA, not available; WI-NRS, worst-itch numeric rating scale; SD, standard deviation.